Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Mylan announced the launch of Tadalafil Tablets, the first generic version of Eli Lilly’s Adcirca. 

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability. PDE5 is the enzyme responsible for the degradation for cyclic guanosine monophosphate (cGMP) and the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. 

Tadalafil should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat). Headache was reported as the most common adverse reaction. 

Mylan’s Tadalafil Tablets will be available in a 20mg strength. The Company has been awarded 180 days of marketing exclusivity for this product. 

For more information call (800) RX-MYLAN or visit Mylan.com.

This article originally appeared on MPR